Turn Therapeutics (NASDAQ:TTRX – Get Free Report) announced its earnings results on Monday. The company reported ($0.03) earnings per share for the quarter, FiscalAI reports.
Turn Therapeutics Price Performance
NASDAQ:TTRX opened at $3.88 on Tuesday. The stock has a market cap of $115.59 million and a price-to-earnings ratio of -24.25. Turn Therapeutics has a one year low of $2.57 and a one year high of $26.50. The business has a fifty day moving average of $3.49.
Wall Street Analyst Weigh In
Separately, D. Boral Capital restated a “buy” rating and issued a $8.00 price objective on shares of Turn Therapeutics in a research note on Tuesday, March 24th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $8.00.
Institutional Investors Weigh In On Turn Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the stock. Wellington Shields & Co. LLC purchased a new stake in shares of Turn Therapeutics in the 4th quarter worth $259,000. Tamar Securities LLC purchased a new stake in shares of Turn Therapeutics in the 4th quarter worth $59,000. DDFG Inc increased its stake in Turn Therapeutics by 34.9% in the 1st quarter. DDFG Inc now owns 70,534 shares of the company’s stock worth $226,000 after buying an additional 18,246 shares in the last quarter. Geode Capital Management LLC purchased a new stake in Turn Therapeutics in the 4th quarter worth $68,000. Finally, Jane Street Group LLC purchased a new stake in Turn Therapeutics in the 4th quarter worth $68,000.
Turn Therapeutics Company Profile
We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.
See Also
- Five stocks we like better than Turn Therapeutics
- Sell in May and Go Away—Starting With These 3 Stocks
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
Receive News & Ratings for Turn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
